IFP Advisors’s Seres Therapeutics MCRB Stock Holding History

IFP Advisors’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-25	Closed	-$11.5K	–	3139
2020 Q4	$12K	Buy	+25	New	+$14.6K	﹤0.01%	1993

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

IFP Advisors's MCRB Position: Q1 2021 in Review

IFP Advisors sold out of Seres Therapeutics (MCRB) in Q1 2021, closing a stake of 25 shares — an estimated $11.5K sold.

IFP Advisors first reported a position in MCRB in Q4 2020 and held it in 1 quarter. The position peaked at $12K in Q4 2020. 152 funds tracked by Wall St. Rank hold MCRB as of Q1 2021.

IFP Advisors reported no remaining Seres Therapeutics position as of Q1 2021 after selling out during the quarter.
IFP Advisors sold 25 Seres Therapeutics shares in Q1 2021, an estimated $11.5K.
IFP Advisors first reported a position in Seres Therapeutics in Q4 2020 and held it in 1 quarter.
IFP Advisors's Seres Therapeutics position peaked at $12K in Q4 2020.
152 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2021.

Based on IFP Advisors's 13F filing for Q1 2021, filed 30 Apr 2021.